- Follow patients for signs and symptoms of respiratory depression and sedation.
- Limit dosages and durations to the minimum required.
Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, patients receiving DSUVIA and any CYP3A4 inhibitor or inducer. Cytochrome P450 3A4 inducer may result in an increase in sufentanil plasma concentration. Monitor cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used
The concomitant use of DSUVIA with all cytochrome P450 3A4 inhibitors may result in an increase
all patients regularly for the development of these behaviors or conditions.

Indications and Usage

DSUVIA is indicated for use in adult patients only in a certified medically supervised healthcare setting. Use of

Limitations of Use:

- Have not provided adequate analgesia, or are not expected to provide adequate analgesia.
- Known hypersensitivity to sufentanil or components of DSUVIA.
- Significant respiratory depression
- Prolonged use of DSUVIA during pregnancy can result in withdrawal in the neonate, which can be life-
- DSUVIA should not be used in patients who may be particularly susceptible to the intracranial effects of CO₂

Efficiently Delivered.

DSUVIA is indicated for the management of acute pain, severe enough to require an opioid analgesic and for which alternative treatments are inadequate, in adults. DSUVIA is for use in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments.
TONGUE AND DONE.